AU2800392A - Induction of protection against viral infection by synergy between viral proteins and viral peptides - Google Patents
Induction of protection against viral infection by synergy between viral proteins and viral peptidesInfo
- Publication number
- AU2800392A AU2800392A AU28003/92A AU2800392A AU2800392A AU 2800392 A AU2800392 A AU 2800392A AU 28003/92 A AU28003/92 A AU 28003/92A AU 2800392 A AU2800392 A AU 2800392A AU 2800392 A AU2800392 A AU 2800392A
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- hiv
- virus
- envelope glycoprotein
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US782154 | 1977-03-28 | ||
US782252 | 1977-03-28 | ||
US782241 | 1985-09-30 | ||
US78215491A | 1991-10-28 | 1991-10-28 | |
US78225291A | 1991-10-28 | 1991-10-28 | |
US78224191A | 1991-10-28 | 1991-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2800392A true AU2800392A (en) | 1993-06-07 |
Family
ID=27419774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU28003/92A Abandoned AU2800392A (en) | 1991-10-28 | 1992-10-28 | Induction of protection against viral infection by synergy between viral proteins and viral peptides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0613378A1 (fr) |
JP (1) | JPH07501052A (fr) |
AU (1) | AU2800392A (fr) |
CA (1) | CA2122263A1 (fr) |
WO (1) | WO1993008836A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09512177A (ja) * | 1994-04-29 | 1997-12-09 | ファルマシア・アンド・アップジョン・カンパニー | ネコ免疫不全ウイルスワクチン |
US6300118B1 (en) | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
FR2769916B1 (fr) * | 1997-10-17 | 2000-12-01 | Centre Nat Rech Scient | Peptides issus du gene env du virus de l'immunodeficience feline et leurs applications immunoprotectrices et vaccinales |
US6641816B1 (en) | 1998-06-26 | 2003-11-04 | Aventis Pasteur S.A. | Use of poxviruses as enhancer of specific immunity |
CA2358385C (fr) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations |
JP4701532B2 (ja) * | 2001-04-26 | 2011-06-15 | 東ソー株式会社 | Hiv−1rnaの増幅および検出法 |
EP1411770A4 (fr) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03271233A (ja) * | 1990-03-19 | 1991-12-03 | Inst Pasteur | ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発 |
-
1992
- 1992-10-28 AU AU28003/92A patent/AU2800392A/en not_active Abandoned
- 1992-10-28 WO PCT/EP1992/002459 patent/WO1993008836A1/fr not_active Application Discontinuation
- 1992-10-28 JP JP5508136A patent/JPH07501052A/ja active Pending
- 1992-10-28 CA CA002122263A patent/CA2122263A1/fr not_active Abandoned
- 1992-10-28 EP EP92922431A patent/EP0613378A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2122263A1 (fr) | 1993-05-13 |
WO1993008836A1 (fr) | 1993-05-13 |
EP0613378A1 (fr) | 1994-09-07 |
JPH07501052A (ja) | 1995-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10946090B2 (en) | Consensus/ancestral immunogens | |
Girard et al. | Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. | |
Girard et al. | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 | |
Earl et al. | Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140 | |
Johnson et al. | Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. | |
Notka et al. | Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies | |
Stratov et al. | Vaccines and vaccine strategies against HIV | |
US5876724A (en) | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein | |
AU2800392A (en) | Induction of protection against viral infection by synergy between viral proteins and viral peptides | |
EP0472706B1 (fr) | Induction de protection contre les infections virales | |
Sheppard | Inactivated-or killed-virus HIV/AIDS vaccines | |
Klein | AIDS and HIV vaccines | |
Stott | Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines | |
CA2722240C (fr) | Compositions et procedes destines a la prevention ou au traitement du sida | |
Silvera et al. | Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques | |
Oxford et al. | Challenges and strategies for AIDS vaccine development | |
Ronco et al. | High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides | |
Rubinstein et al. | Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates | |
US20170107260A1 (en) | Mosaic hiv-1 sequences and uses thereof | |
Lu | HIV-1 vaccine candidate evaluation in non-human primates | |
Hallengärd | Strategies to enhance the potency of HIV-1 DNA vaccines | |
Girard et al. | Report of the 2014 Cent Gardes HIV Vaccine Conference—Part 2: Cell-mediated immunity, mucosal protection, and clinical trials: Fondation Mérieux Conference Center, Veyrier du Lac, France, 5–7 October, 2014 | |
Langhammer | Neutralisierende Antikörper gegen die transmembranen Hüllproteine von Retroviren | |
Schultz | Designing a vaccine against HIV | |
Mosley et al. | 2.3 HIV-1 vaccines |